MedTrace Logo

Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

NCT03647137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2024-01-05

Study results available
· View outcomes & findings →

Summary

Early stage Parkinson disease (PD) is characterized by a 'honeymoon' phase in terms of responsiveness of motor symptoms, including gait, to dopaminergic pharmacotherapy. Advancing PD is associated with disabling axial motor complications, such as freezing of gait (FoG), with decreased or even refractory dopamine responsiveness in over 50% of patients. The management of dopamine resistant gait problems represents the most important unmet need in PD. This study will related detailed motor testing to brain PET imaging to see if certain molecules (or lack thereof) involved with neurologic transmission in the brain are involved with FoG.

Conditions

Interventions

OTHER

Detailed motor testing, including FoG, in PD subjects

Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic "on" and "off" state.

Sponsors & Collaborators

Principal Investigators

  • Nicolaas I Bohnen, MD PhD · VA Ann Arbor Healthcare System, Ann Arbor, MI

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-07
Primary Completion
2021-05-26
Completion
2021-05-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03647137 on ClinicalTrials.gov